151539-30-9

Basic information

• Product Name: (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine
• Synonyms: (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine
• CAS NO: 151539-30-9
• Molecular Formula: C22H28 N4 O2
• Molecular Weight: 380.48
• Mol File: 151539-30-9.mol

Chemical Properties

• Boiling Point: 583.4°Cat760mmHg
• Flash Point: 306.6°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 1.34E-13mmHg at 25°C
• Refractive Index: 1.597
• CAS DataBase Reference: (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine(151539-30-9)
• EPA Substance Registry System: (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine(151539-30-9)

Safety Data

• Hazardous Substances Data: 151539-30-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine is used as a therapeutic agent for the treatment of neurological and psychiatric disorders. Its application is based on its ability to act as a selective adenosine A2A receptor antagonist, which has shown potential in managing conditions such as Parkinson's disease, depression, and drug addiction.
Used in Cognitive Enhancement:
(E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine is also used as a cognitive enhancer due to its potential to improve cognitive function. (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine's interaction with adenosine receptors in the brain may contribute to its cognitive-enhancing properties.
Used in Research and Development:
In addition to its therapeutic and cognitive enhancement applications, (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine is used in the research and development of new drugs and therapies. Its unique chemical structure and receptor binding properties make it a valuable tool for studying the role of adenosine receptors in various diseases and conditions.

InChI:InChI=1/C22H28N4O2/c1-6-12-25-20-19(21(27)26(13-7-2)22(25)28)24(5)18(23-20)11-10-17-9-8-15(3)16(4)14-17/h8-11,14H,6-7,12-13H2,1-5H3/b11-10+

Relevant articles and documents

Antidepressants

The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : STR1 in which R1, R2, and R3 represent independently hydrogen, lower alkyl, lower alkenyl; R4 represents cycloalkyl, --(CH2)n --R5 (in which R5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 (in which Y1 and Y2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 (in which R6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group); and X1 and X2 represent independently O or S.

Therapeutic agent for Parkinson's disease

Agents for the treatment of Parkinson''s disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: STR1 in which R 1, R 2 are R 3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R 4 represents cycloalkyl, --(CH 2) n --R 5 (in which R 5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 in which Y 1 and Y 2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 in which R 6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X 1 and X 2 represent independently O or S.